AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10977396
Drug: No vaccination
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No vaccination and treatment
Trial: 8783051
Drug: Colgate 0-6
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colgate 0-6 gel
Trial: 1731288
Drug: Routine weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Routine weekly cervical examinations at term (from 37 weeks until delivery)
Trial: 1731288
Drug: Routine weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Routine weekly cervical examinations at term
Trial: 30565892
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (50,000 IU monthly)
Trial: 25239216
Drug: Control (CON)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (CON) group (placebo solution)
Trial: 20157677
Drug: Preparation walls
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation walls (pulpal, axial, gingival)
Trial: 17306498
Drug: New agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New agents for treating castration-resistant prostate cancer
Trial: 11879139
Drug: Topical unoprostone
RxNorm normalized name: unoprostone
DrugBank: Unoprostone (DB06826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical unoprostone
Trial: 11879139
Drug: ET-1 administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ET-1 administration
Trial: 10673968
Drug: Patient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient treatment preferences
Trial: 2138477
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Adriamycin i.v. weekly (Awkly)
Trial: 2138477
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg 4‐epidoxorubicin biweekly (EPIbiwkly)
Trial: 6766411
Drug: Phosphate infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate infusions (62 ± 5 mmol sodium phosphate)
Trial: 6766411
Drug: Standardized conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized conventional treatment alone
Trial: 29974963
Drug: Omalizumab 300
RxNorm normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab 300 mg administered subcutaneously every 4 weeks for 12 weeks
Trial: 26669545
Drug: Immediate post-extractive
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate post-extractive implants
Trial: 28327692
Drug: Immediate-delayed implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-delayed implants at 6 weeks
Trial: 28327692
Drug: Delayed implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implants after 4 months
Trial: 25821849
Drug: High-fluoride dentifrice
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fluoride dentifrice (5000 µg F/g)
Trial: 25821849
Drug: Conventional fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fluoride dentifrice (1100 µg F/g)
Trial: 23543359
Drug: Prime Time
RxNorm normalized name: ZINC OXIDE 10.49 g in 100 g / TITANIUM DIOXIDE 3.13 g in 100 g TOPICAL LOTION [Prime Time Daily Protecting Primer SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prime Time intervention (dose-response analysis)
Trial: 19848209
Drug: Oral hypoglycemic
RxNorm normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypoglycemic drugs (glipizide, pioglitazone, metformin) and antihypertensive drug (nifedipine)
Trial: 17489878
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg telmisartan/day
Trial: 17489878
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg irbesartan/day
Trial: 17489878
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma insulin (FPI)
Trial: 11506246
Drug: Steroids (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids (oral prednisone 1.0 mg/Kg/day for 2 months, tapered by 0.2 mg/Kg/day every month) plus ramipril (2.5 mg/day for one month, increased by 1.25 mg/day every month)
Trial: 11506246
Drug: Steroids plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids plus ramipril
Trial: 9754987
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg alone
Trial: 9754987
Drug: Caffeine 150
RxNorm normalized name: caffeine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 150 mg alone
Trial: 9754987
Drug: Caffeine 300
RxNorm normalized name: caffeine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 300 mg with zolpidem
Trial: 9754987
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg with caffeine 250 mg
Trial: 8116706
Drug: Prophylactic penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic penicillin (1 million units of benzylpenicillin intravenously every 4 hours followed by 250 mg of potassium phenoxymethyl penicillin orally twice daily)
Trial: 146511
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate (0.4 g daily)
Trial: 23644090
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin therapy (rosuvastatin 40 mg daily)
Trial: 23644090
Drug: Standard-of-care lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care lipid-lowering therapy
Trial: 21325901
Drug: Intrathecal meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal meperidine 12.5 mg (M1)
Trial: 21325901
Drug: Intrathecal meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal meperidine 25 mg (M2)
Trial: 21325901
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (M0) with bupivacaine 0.5% (10 mg)
Trial: 21325901
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of meperidine (M1 and M2)
Trial: 16433203
Drug: 4-shot allergy
RxNorm normalized name: ChoreMate One-Shot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-shot allergy vaccine (Pollinex Quattro) containing appropriate allergoids (grass/rye and/or mugwort) adsorbed to L-tyrosine plus a Th1 adjuvant, monophosphoryl lipid A (MPL)
Trial: 16433203
Drug: 4-shot allergy
RxNorm normalized name: ChoreMate One-Shot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-shot allergy vaccine (Pollinex Quattro)
Trial: 16433203
Drug: Control challenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control challenges (similar pollen vaccine without MPL and a tree pollen vaccine with and without MPL)
Trial: 12877821
Drug: Formoterol 12
RxNorm normalized name: formoterol 12 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 12 microg twice daily in addition to beclomethasone 500 microg twice daily
Trial: 12877821
Drug: Beclomethasone 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone 1000 microg twice daily and placebo
Trial: 9950912
Drug: TNFR:Fc (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFR:Fc (6 mg/m2)
Trial: 26115589
Drug: Carbohydrate‐electrolyte gels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate‐electrolyte gels (0.7±0.1gkg(‐1) BM)
Trial: 26115589
Drug: Energy-free placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-free placebo gels
Trial: 25310201
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 50, 70, 100, 150, 200, and 250 mg daily for 5 days
Trial: 19696435
Drug: FFW-L/NBLI and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFW-L/NBLI and NBLI/FFW-L (combined intervention groups)
Trial: 16141467
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite (1,000 microg administered intravenously or orally daily for 3 weeks)
Trial: 10102147
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (14.2 mg elemental zinc for first 417 patients and 40 mg for remaining 273 patients) for 15 days
Trial: 2185023
Drug: Carbochromen (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbochromen (0.125 mg kg‐1 min‐1 for 40 min i.v.)
Trial: 2185023
Drug: Dipyridamole (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (0.05 mg kg‐1 min‐1 for 10 min i.v.)
Trial: 399859
Drug: Continuous salbutamol
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous salbutamol tablets
Trial: 399859
Drug: Intermittent salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent salbutamol tablets
Trial: 30982716
Drug: No pain
RxNorm normalized name: Biochemistry Heel No Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pain medication
Trial: 31299447
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo nasal spray with expectancy-modifying instructions (Protection: the spray protects from experiencing negative emotions)
Trial: 31299447
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Sensitization: the spray sensitizes to negative emotions)
Trial: 31299447
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Placebo: the spray is a placebo)
Trial: 31299447
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Control: no nasal spray)
Trial: 28547075
Drug: Suprascapular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprascapular nerve (SSN)‐pulsed radiofrequency (RF) therapy
Trial: 28547075
Drug: Both PBMT
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both PBMT and SSN-pulsed RF therapy
Trial: 21599941
Drug: Specific physiotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific physiotherapy treatment (10 sessions over 10 weeks)
Trial: 21599941
Drug: Specific physiotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific physiotherapy treatment
Trial: 12817519
Drug: ICL670 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICL670 2.5 to 80 mg/kg
Trial: 12817519
Drug: ICL670 40-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICL670 40- and 80-mg/kg dose levels
Trial: 8656257
Drug: Reintroduction chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reintroduction chemotherapy
Trial: 8656257
Drug: Reintroduction chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reintroduction chemotherapy for women aged > or = 40 years
Trial: 6340601
Drug: Ceftazidime 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 1.5 g daily
Trial: 6340601
Drug: Ceftazidime 3
RxNorm normalized name: ceftazidime 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 3 g daily
Trial: 31238907
Drug: Internet-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioral treatment (9 sessions)
Trial: 28121935
Drug: Citicoline therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline therapy at 0.6 g/d for 1 year
Trial: 28121935
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no central nervous system drugs except sleeping pills and antidepressants)
Trial: 16685052
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (GFJ) 240 mL with felodipine 10 mg
Trial: 16685052
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice 240 mL with felodipine 10 mg
Trial: 16685052
Drug: Furanocoumarin-free grapefruit
RxNorm normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furanocoumarin-free grapefruit juice 240 mL with felodipine 10 mg
Trial: 15474877
Drug: Sodium-restricted diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-restricted diet (2000 to 2400 mg/d) with restriction of total fluids to 1.5 L/d
Trial: 15474877
Drug: Traditional medical
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional medical treatment and general nutritional recommendations
Trial: 10980174
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg once daily for 10 days
Trial: 9892527
Drug: Polymyxin B-immobilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymyxin B-immobilized fibre (PMX-F) treatment
Trial: 2738584
Drug: Subcutaneous hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous hepatitis B vaccine
Trial: 21364482
Drug: Carbohydrate and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate and protein solution (CHO + P) providing 0.49 and 0.16 g·kg(‐1)·h(‐1)
Trial: 21364482
Drug: Carbohydrate solution
RxNorm normalized name: phosphorated carbohydrate solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate solution (CHO) providing 0.49 g·kg(‐1)·h(‐1)
Trial: 21364482
Drug: Carbohydrate and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate and protein solution (CHO + P)
Trial: 11935108
Drug: Sherbrooke model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sherbrooke model (combination of clinical-rehabilitation and occupational interventions)
Trial: 10412300
Drug: Systemic palliative
RxNorm normalized name: Various pain palliation radiopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic palliative chemotherapy with 5-fluorouracil and leucovorin
Trial: 7549760
Drug: Trained health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trained health workers (HWs) conducting oral visual inspections
Trial: 2247650
Drug: Standard 10
RxNorm normalized name: grass pollen-timothy, standard 10,000 bioequiv. allergy unit/mL INJECTION VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 10 Gy single dose TBI
Trial: 7470371
Drug: Nicotine 500
RxNorm normalized name: Nicotine 500 microgram/actuation nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 500 μg
Trial: 7470371
Drug: Nicotine 750
RxNorm normalized name: niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 750 μg
Trial: 7470371
Drug: Range of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Range of nicotine doses from 12.5 to 800 μg
Trial: 6403254
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy consisting of cis‐platinum 40 mg/m2 IV on day 1, adriamycin 40 mg/m2 IV on day 1, and hexamethylmelamine 150 mg/m2 PO on days 2‐10 up to a maximum of 200 mg on a 4‐weekly cycle.
Trial: 6403254
Drug: Moderate‐dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate‐dose cyclophosphamide alone 40 mg/kg given IV intermittently every 3 weeks.
Trial: 28065179
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (1.5 g/d n-3 LCPUFA)
Trial: 7068895
Drug: Habit reversal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habit reversal treatment
Trial: 21664779
Drug: Neoadjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant endocrine therapy (NAE)
Trial: 20051135
Drug: MF‐DPI 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF‐DPI 400 microg once‐daily in the evening
Trial: 20051135
Drug: MF‐DPI 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF‐DPI 200 microg twice‐daily
Trial: 20051135
Drug: Self-reports for
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-reports for MF‐DPI 400 microg once‐daily
Trial: 20051135
Drug: Self-reports for
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-reports for MF‐DPI 200 microg twice‐daily
Trial: 17942035
Drug: Sulpiride (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (50 mg/8 h)
Trial: 17118597
Drug: Sulpiride (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (50 mg/8 h) plus Hydroxyzine (25 mg/12 h)
Trial: 16244511
Drug: General program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General program of psychomotor therapy (different forms of physical exercises and relaxation training)
Trial: 11838838
Drug: keliximab 40
RxNorm normalized name: Galiximab
DrugBank: Galiximab (DB04901)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: keliximab 40 mg twice weekly (bw)
Trial: 11838838
Drug: keliximab 80
RxNorm normalized name: Galiximab
DrugBank: Galiximab (DB04901)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: keliximab 80 mg bw
Trial: 11838838
Drug: keliximab 140
RxNorm normalized name: Galiximab
DrugBank: Galiximab (DB04901)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: keliximab 140 mg bw
Trial: 11838838
Drug: keliximab 240
RxNorm normalized name: Galiximab
DrugBank: Galiximab (DB04901)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: keliximab 240 mg once weekly (ow)
Trial: 11838838
Drug: keliximab 120
RxNorm normalized name: Galiximab
DrugBank: Galiximab (DB04901)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: keliximab 120 mg bw
Trial: 2405733
Drug: Oral caffeine
RxNorm normalized name: caffeine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral caffeine (300 mg)
Trial: 11216966
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant therapy
Trial: 31427637
Drug: Nurse-led follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led follow-up and medical titration by telephone to reach set intervention targets
Trial: 26295379
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care intervention for chronic pain; details on dosage and duration not specified.
Trial: 24510678
Drug: Cangrelor (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cangrelor (specific receptor antagonist for P2Y12)
Trial: 17922978
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 200 microg once daily in the evening
Trial: 17922978
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 400 microg twice daily (BID)
Trial: 17922978
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 200-400 microg once daily
Trial: 15695959
Drug: Physical therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapies and shoulder arthrography with intra-articular steroid
Trial: 15695959
Drug: Physical therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapies alone
Trial: 10047935
Drug: 2.5 mg/d
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/d of deprenyl
Trial: 10047935
Drug: 10 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/d of deprenyl
Trial: 7267221
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: Blood phenylalanine target 1.0 to 5.4 mg/100 ml
Trial: 7267221
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: Blood phenylalanine target 5.5 to 9.9 mg/100 ml
Trial: 9108785
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment groups